Your Article Summary
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
Lung Cancer, 06/29/09
Wu JY et al. - Gefitinib is effective as a second-line therapy for previously treated NSCLC patients. The effectiveness was influenced by EGFR status rather than previous chemotherapy regimens.
Related Articles
Treatment after the Failure of Gefitinib in Patients with Advanced or Recurrent Non-small Cell Lung Cancer
Anticancer Research, 11/13/09
Relevance Score: 91%
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification
Cancer Science, 10/08/09
Relevance Score: 87%
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations
Investigational New Drugs, 10/08/09
Relevance Score: 87%
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
Investigational New Drugs, 10/08/09
Relevance Score: 87%
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Relevance Score: 84%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis
Journal of Cystic Fibrosis , 12/02/09
Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
Emergency Medicine Journal, 12/02/09
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer
Journal of Clinical Oncology, 12/01/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer
The Oncologist, 12/02/09
Prognostic Factors for Resected Non-Small Cell Lung Cancer with pN2 Status: Implications for Use of Postoperative Radiotherapy
The Oncologist, 12/02/09
Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors
Annals of Surgical Oncology, 12/02/09

See Latest Articles